Renal Biomarkers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product Type (Functional Biomarker, Serum Creatinine, Serum Cystatin C, Urine Albumin, Up-regulated Protein, Neutrophil Gelatinase-Associated Lipocalin (NGAL), Kidney Injury Molecule-1, INTERLEUKIN-18, Others), By Technique (Enzyme-linked Immunosorbent Assay (ELISA), Particle-enhanced Turbidimetric Immunoassay (PETIA), Colorimetric Assay, Chemiluminescent Enzyme Immunoassay (CLIA), Liquid Chromatography Mass Spectrometry (LC-MS)), By End user (Hospitals & Clinics, Diagnostic Laboratory, Others), By Region and Competition

Industry : Healthcare
Pages : NA
Published Date : NA

Customization Enquiry

Buy Now

Single User Licence

$4500

Multi-User Licence

$5500

Custom Research Licence

$8000

Summary

Request Sample

Report Description

Forecast Period	2024-2028
Market Size (2022)	USD 1.31 Billion
CAGR (2023-2028)	7.25%
Fastest Growing Segment	Serum Cystatin C
Largest Market	North America

Market Overview

Global Renal Biomarkers Market has valued at USD 1.31 Billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.25% through 2028. The global renal biomarkers market has witnessed significant growth in recent years, driven by an increasing prevalence of kidney diseases and a growing demand for early disease detection and management. Renal biomarkers play a crucial role in diagnosing and monitoring various kidney-related disorders, making them invaluable tools in the field of healthcare. Renal biomarkers are molecules or substances that are found in the blood, urine, or other bodily fluids and provide valuable information about the status and function of the kidneys. These biomarkers can help healthcare professionals detect kidney diseases at an early stage, assess the severity of kidney injury, and monitor the effectiveness of treatment. Common renal biomarkers include serum creatinine, urinary albumin, and estimated glomerular filtration rate (eGFR). The increasing prevalence of chronic kidney disease (CKD) and other kidney-related disorders, such as acute kidney injury (AKI) and diabetic nephropathy, is a primary driver of the renal biomarkers market. Aging populations and the global diabetes epidemic have contributed to the growing burden of kidney diseases. Early diagnosis and intervention are essential for managing kidney diseases effectively. Renal biomarkers provide a non-invasive and convenient means of diagnosing and monitoring kidney disorders, making them indispensable tools for healthcare providers. Advances in technology have led to the development of more sensitive and specific renal biomarker assays. Novel biomarkers and improved detection methods are enhancing the accuracy of kidney disease diagnosis and prognosis. The trend towards personalized medicine is also impacting the renal biomarkers market. Tailored treatment plans based on a patient's unique biomarker profile are becoming more common, improving the overall management of kidney diseases.

Key Market Drivers

Rising Prevalence of Kidney Diseases is Driving the Global Renal Biomarkers Market

Kidney diseases are becoming increasingly prevalent worldwide, posing a significant healthcare challenge. These conditions can lead to severe health complications and, in some cases, even be life-threatening. The rising incidence of kidney diseases has prompted extensive research in the medical field, leading to the development and adoption of renal biomarkers. These biomarkers have played a crucial role in early diagnosis, monitoring, and treatment of kidney diseases, driving the global renal biomarkers market forward. Kidney diseases encompass a range of conditions affecting the vital organs responsible for filtering waste products and excess fluid from the blood, maintaining electrolyte balance, and producing hormones to regulate blood pressure and red blood cell production. Common kidney diseases include chronic kidney disease (CKD), acute kidney injury (AKI), kidney stones, and polycystic kidney disease (PKD).

The global prevalence of kidney diseases has been on the rise for several reasons. First and foremost is the increasing prevalence of risk factors such as diabetes, hypertension, and obesity. These conditions are known to be significant contributors to kidney disease development. Additionally, an aging population and lifestyle factors like smoking and poor dietary choices have added to the burden of kidney diseases. Inadequate awareness and late-stage diagnosis have exacerbated the problem. Kidney diseases often progress silently, with symptoms only becoming apparent in the advanced stages. Early detection is crucial for effective intervention and management, making renal biomarkers a vital tool in the fight against kidney diseases.

Renal biomarkers are measurable indicators, such as proteins or molecules found in bodily fluids, that provide valuable information about kidney function. These biomarkers help healthcare professionals in various aspects of kidney disease management. Biomarkers can detect kidney dysfunction before symptoms manifest, allowing for early intervention and improved outcomes. Renal biomarkers enable continuous monitoring of kidney function, helping doctors assess the progression of the disease and make necessary treatment adjustments.

Increased Drug Development and Clinical Trials is Driving the Global Renal Biomarkers Market

Renal biomarkers have become indispensable in the drug development process. They play a pivotal role in various phases of clinical trials, from patient selection and monitoring to assessing treatment efficacy and safety. Renal biomarkers help identify suitable participants for clinical trials by providing insights into the severity and stage of kidney disease. This ensures that the right patients are enrolled, improving trial accuracy and outcomes. During clinical trials, renal biomarkers are used to monitor how drugs impact kidney function. This allows researchers to assess the safety and efficacy of potential treatments. Renal biomarkers can help detect kidney-related adverse events in clinical trial participants, enabling prompt intervention and minimizing potential harm. Biomarker data can aid in the development of personalized treatment plans, allowing clinicians to tailor therapies to individual patients based on their specific kidney profiles.

Government agencies, pharmaceutical companies, and research organizations worldwide have recognized the importance of addressing kidney diseases. Consequently, there has been a surge in initiatives, collaborations, and investments aimed at advancing renal biomarker research. These endeavors are driving innovation and accelerating the development of novel diagnostics and therapeutics. As drug development and clinical trials continue to expand, the global renal biomarkers market is poised for significant growth. Emerging technologies, such as artificial intelligence and machine learning, are enhancing our ability to identify and validate novel biomarkers quickly. Additionally, the integration of multi-omics data (genomics, proteomics, metabolomics) is providing a more comprehensive understanding of kidney diseases, leading to the discovery of new biomarkers.

Download Free Sample Report

Key Market Challenges

Limited Biomarker Validation

One of the primary challenges facing the renal biomarkers market is the limited validation of biomarkers. The development of reliable and accurate renal biomarkers requires extensive research and clinical trials to establish their efficacy and specificity. The validation process is time-consuming and expensive, and many potential biomarkers do not meet the necessary criteria for clinical use. As a result, the market faces a shortage of well-validated biomarkers, hindering its growth potential.

Regulatory Hurdles

Regulatory approvals are essential for the commercialization of renal biomarkers. The regulatory pathway for biomarker approval can be complex and varies from one region to another. Meeting the stringent requirements of regulatory agencies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) can be a lengthy and costly process. Navigating these regulatory hurdles can delay the market entry of new biomarkers and increase the overall cost of product development.

Reimbursement Challenges

Reimbursement is a critical factor in the adoption of renal biomarkers in clinical practice. Healthcare providers and payers need to determine the cost-effectiveness of using biomarkers for renal disease diagnosis and management. Convincing payers to reimburse for these tests can be challenging, especially if the cost-benefit ratio is not clearly established. Demonstrating the long-term cost savings and improved patient outcomes associated with biomarker use is essential to overcome this hurdle.

Competition and Market Saturation

The renal biomarkers market is becoming increasingly competitive, with multiple companies and research institutions vying to develop and commercialize new biomarkers. As the number of players in the market grows, it becomes harder for individual biomarkers to stand out. Market saturation can also lead to price competition, potentially affecting the profitability of biomarker developers.

Data Privacy and Ethical Concerns

With the growing use of biomarkers, concerns about data privacy and ethical issues related to patient information and biological samples have come to the forefront. Maintaining patient confidentiality and ensuring that data is used responsibly is a significant challenge, especially as biomarker research often involves extensive data collection and analysis.

Clinical Utility and Physician Adoption

For renal biomarkers to gain widespread acceptance, they must demonstrate clear clinical utility and be adopted by healthcare professionals. Physicians may be resistant to change and hesitant to incorporate new biomarkers into their diagnostic and treatment algorithms, especially if they are unfamiliar with their use or if there is insufficient evidence of their clinical benefit.

Key Market Trends

Technological Advancements

The global healthcare landscape has witnessed remarkable transformations in recent years, driven by rapid technological advancements. One area that has benefited significantly from these innovations is the diagnosis and treatment of renal diseases. The Global Renal Biomarkers Market is experiencing substantial growth as cutting-edge technologies continue to reshape the way we understand, diagnose, and manage renal conditions. Renal biomarkers are playing a pivotal role in this evolution, enabling early detection, precise diagnosis, and personalized treatment plans.

The development of advanced diagnostic tools, such as mass spectrometry and next-generation sequencing, has revolutionized the identification of renal biomarkers. These technologies allow for the rapid and accurate analysis of biological samples, enabling the detection of even subtle changes in renal function. Data analytics and artificial intelligence (AI) have become integral to the analysis of renal biomarker data. AI algorithms can process vast amounts of patient data, identifying patterns and trends that may be missed by human clinicians. This enhances the accuracy of renal disease diagnosis and the prediction of disease progression. Technological advancements have enabled the move toward personalized medicine in the field of nephrology. Renal biomarkers are used to tailor treatment plans to individual patients, taking into account their unique genetic makeup and disease characteristics. This approach improves treatment outcomes and reduces the risk of adverse effects. Miniaturization and portable diagnostic devices have made it possible to perform renal biomarker testing at the point of care. This is particularly important in remote or underserved areas where access to centralized laboratories may be limited. Point-of-care testing allows for quicker diagnosis and treatment initiation.

Segmental Insights

Product Type Insights

Based on the category of Product Type, Serum Cystatin C emerged as the dominant player in the global market for Renal Biomarkers in 2022. erum Cystatin C is a small protein produced by all nucleated cells at a constant rate and is freely filtered by the glomerulus in the kidneys. Unlike other traditional biomarkers like serum creatinine, Serum Cystatin C is less influenced by factors such as age, gender, muscle mass, and diet, making it a more reliable marker of renal function. Serum Cystatin C is sensitive to changes in glomerular filtration rate (GFR), making it a valuable tool for the early detection of kidney dysfunction. It can detect renal impairment even when serum creatinine levels remain within the normal range. Unlike creatinine-based estimates of GFR, Serum Cystatin C offers better precision in estimating renal function, especially in patients with conditions affecting muscle mass or dietary habits. Serum Cystatin C levels show less day-to-day variability compared to creatinine, making it a more consistent marker for monitoring renal function over time. Research has shown that elevated Serum Cystatin C levels are associated with a higher risk of adverse outcomes in patients with renal diseases, including progression to end-stage renal disease and cardiovascular events.

End user Insights

The Hospitals & Clinics segment is projected to experience rapid growth during the forecast period. Hospitals and clinics are primary healthcare settings where patients seek medical care, including kidney-related issues. These institutions see a high volume of patients with diverse medical conditions, making them key locations for renal biomarker testing. This sheer patient access ensures a consistent demand for renal biomarkers. Hospitals, in particular, are equipped with advanced diagnostic laboratories and imaging equipment. This infrastructure enables healthcare professionals to conduct a wide range of tests, including renal biomarker assays, with precision and efficiency. This makes hospitals and clinics natural hubs for renal biomarker testing. Renal biomarkers are often used in conjunction with other diagnostic tools and tests. Hospitals and clinics offer a multidisciplinary approach to healthcare, bringing together specialists from various fields such as nephrology, cardiology, and endocrinology. This approach facilitates comprehensive patient evaluation and accurate diagnosis. Many hospitals are affiliated with research institutions and universities, which fosters a culture of innovation and continuous research in the medical field. This environment promotes the development of new renal biomarkers and the improvement of existing ones. The rising global prevalence of chronic diseases, including diabetes and hypertension, has led to a surge in kidney-related conditions. Hospitals and clinics are at the forefront of managing these chronic diseases, resulting in an increased need for renal biomarker testing.

Download Free Sample Report

Regional Insights

North America emerged as the dominant player in the global Renal Biomarkers market in 2022, holding the largest market share in terms of value. North America boasts a robust healthcare infrastructure, including world-renowned research institutions and pharmaceutical companies. This environment encourages continuous research and development efforts in the field of renal biomarkers. Leading academic institutions collaborate with industry players to develop innovative biomarkers, diagnostic tests, and treatment strategies. The United States, in particular, is at the forefront of technological advancements in healthcare. Advanced diagnostic tools, such as mass spectrometry and immunoassays, are widely available in North American laboratories, facilitating the detection and quantification of renal biomarkers with precision and accuracy. North America has well-established regulatory bodies, such as the U.S. Food and Drug Administration (FDA) and Health Canada, which provide a clear pathway for biomarker approval and commercialization. Stringent regulatory oversight ensures that only high-quality and reliable biomarkers enter the market, instilling confidence in healthcare professionals and patients alike.

Recent Developments

In April 2021, Renalytix AI expanded its collaboration with the Joslin Diabetes Center to incorporate recently identified kidney disease biomarkers from the center's researchers into the KidneyIntelX platform. KidneyIntelX is an in vitro diagnostic tool designed to evaluate the likelihood of unfavorable kidney outcomes in individuals with Type 2 diabetes and initial-stage kidney disease. It accomplishes this by analyzing a patient's blood sample and medical history, ultimately producing a risk score for disease advancement. This risk score aids healthcare professionals in forecasting the progression of chronic kidney disease (CKD) and making informed decisions regarding treatments to mitigate the decline in kidney function.

Key Market Players

Abbott Laboratories
Beckman Coulter Inc. (Danaher Corporation)
bioMerieux SA
BioPorto A/S
Bio-Rad Laboratories Inc.
Enzo Biochem Inc.
F. Hoffmann-La Roche AG
PerkinElmer Inc.
Randox Laboratories Ltd.
Siemens AG
Thermo Fisher Scientific Inc.

By Product Type	By Technique	By End user	By Region
Functional Biomarker Serum Creatinine Serum Cystatin C Urine Albumin Up-regulated Protein Neutrophil Gelatinase-Associated Lipocalin (NGAL) Kidney Injury Molecule-1 INTERLEUKIN-18 Others	Enzyme-linked Immunosorbent Assay (ELISA) Particle-enhanced Turbidimetric Immunoassay (PETIA) Colorimetric Assay Chemiluminescent Enzyme Immunoassay (CLIA) Liquid Chromatography Mass Spectrometry (LC-MS)	Hospitals & Clinics Diagnostic Laboratory Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Renal Biomarkers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Renal Biomarkers Market, By Product Type:

o Functional Biomarker

o Serum Creatinine

o Serum Cystatin C

o Urine Albumin

o Up-regulated Protein

o Neutrophil Gelatinase-Associated Lipocalin (NGAL)

o Kidney Injury Molecule-1

o INTERLEUKIN-18

o Others

Renal Biomarkers Market, By Technique:

o Enzyme-linked Immunosorbent Assay (ELISA)

o Particle-enhanced Turbidimetric Immunoassay (PETIA)

o Colorimetric Assay

o Chemiluminescent Enzyme Immunoassay (CLIA)

o Liquid Chromatography Mass Spectrometry (LC-MS)

Renal Biomarkers Market, By End user:

o Hospitals & Clinics

o Diagnostic Laboratory

o Others

Renal Biomarkers Market, By Region:

o North America

§ United States

§ Canada

§ Mexico

o Europe

§ France

§ United Kingdom

§ Italy

§ Germany

§ Spain

o Asia-Pacific

§ China

§ India

§ Japan

§ Australia

§ South Korea

o South America

§ Brazil

§ Argentina

§ Colombia

o Middle East & Africa

§ South Africa

§ Saudi Arabia

§ UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Renal Biomarkers Market.

Available Customizations:

Global Renal Biomarkers market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Global Renal Biomarkers Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1. Product Overview

1.1. Market Definition

1.2. Scope of the Market

1.2.1. Markets Covered

1.2.2. Years Considered for Study

1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study

2.2. Baseline Methodology

2.3. Key Industry Partners

2.4. Major Association and Secondary Sources

2.5. Forecasting Methodology

2.6. Data Triangulation & Validation

2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market

3.2. Overview of Key Market Segmentations

3.3. Overview of Key Market Players

3.4. Overview of Key Regions/Countries

3.5. Overview of Market Drivers, Challenges, Trends

4. Global Renal Biomarkers Market Outlook

4.1. Market Size & Forecast

4.1.1. By Value

4.2. Market Share & Forecast

4.2.1. By Product Type (Functional Biomarker, Serum Creatinine, Serum Cystatin C, Urine Albumin, Up-regulated Protein, Neutrophil Gelatinase-Associated Lipocalin (NGAL), Kidney Injury Molecule-1, INTERLEUKIN-18, Others)

4.2.2. By Technique (Enzyme-linked Immunosorbent Assay (ELISA), Particle-enhanced Turbidimetric Immunoassay (PETIA), Colorimetric Assay, Chemiluminescent Enzyme Immunoassay (CLIA), Liquid Chromatography Mass Spectrometry (LC-MS))

4.2.3. By End user (Hospitals & Clinics, Diagnostic Laboratory, Others)

4.2.4. By Region

4.2.5. By Company (2022)

4.3. Market Map

4.3.1. By Product Type

4.3.2. By Technique

4.3.3. By End user

4.3.4. By Region

5. Asia Pacific Renal Biomarkers Market Outlook

5.1. Market Size & Forecast

5.1.1. By Value

5.2. Market Share & Forecast

5.2.1. By Product Type

5.2.2. By Technique

5.2.3. By End user

5.2.4. By Country

5.3. Asia Pacific: Country Analysis

5.3.1. China Renal Biomarkers Market Outlook

5.3.1.1. Market Size & Forecast

5.3.1.1.1. By Value

5.3.1.2. Market Share & Forecast

5.3.1.2.1. By Product Type

5.3.1.2.2. By Technique

5.3.1.2.3. By End user

5.3.2. India Renal Biomarkers Market Outlook

5.3.2.1. Market Size & Forecast

5.3.2.1.1. By Value

5.3.2.2. Market Share & Forecast

5.3.2.2.1. By Product Type

5.3.2.2.2. By Technique

5.3.2.2.3. By End user

5.3.3. Australia Renal Biomarkers Market Outlook

5.3.3.1. Market Size & Forecast

5.3.3.1.1. By Value

5.3.3.2. Market Share & Forecast

5.3.3.2.1. By Product Type

5.3.3.2.2. By Technique

5.3.3.2.3. By End user

5.3.4. Japan Renal Biomarkers Market Outlook

5.3.4.1. Market Size & Forecast

5.3.4.1.1. By Value

5.3.4.2. Market Share & Forecast

5.3.4.2.1. By Product Type

5.3.4.2.2. By Technique

5.3.4.2.3. By End user

5.3.5. South Korea Renal Biomarkers Market Outlook

5.3.5.1. Market Size & Forecast

5.3.5.1.1. By Value

5.3.5.2. Market Share & Forecast

5.3.5.2.1. By Product Type

5.3.5.2.2. By Technique

5.3.5.2.3. By End user

6. Europe Renal Biomarkers Market Outlook

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Product Type

6.2.2. By Technique

6.2.3. By End user

6.2.4. By Country

6.3. Europe: Country Analysis

6.3.1. France Renal Biomarkers Market Outlook

6.3.1.1. Market Size & Forecast

6.3.1.1.1. By Value

6.3.1.2. Market Share & Forecast

6.3.1.2.1. By Product Type

6.3.1.2.2. By Technique

6.3.1.2.3. By End user

6.3.2. Germany Renal Biomarkers Market Outlook

6.3.2.1. Market Size & Forecast

6.3.2.1.1. By Value

6.3.2.2. Market Share & Forecast

6.3.2.2.1. By Product Type

6.3.2.2.2. By Technique

6.3.2.2.3. By End user

6.3.3. Spain Renal Biomarkers Market Outlook

6.3.3.1. Market Size & Forecast

6.3.3.1.1. By Value

6.3.3.2. Market Share & Forecast

6.3.3.2.1. By Product Type

6.3.3.2.2. By Technique

6.3.3.2.3. By End user

6.3.4. Italy Renal Biomarkers Market Outlook

6.3.4.1. Market Size & Forecast

6.3.4.1.1. By Value

6.3.4.2. Market Share & Forecast

6.3.4.2.1. By Product Type

6.3.4.2.2. By Technique

6.3.4.2.3. By End user

6.3.5. United Kingdom Renal Biomarkers Market Outlook

6.3.5.1. Market Size & Forecast

6.3.5.1.1. By Value

6.3.5.2. Market Share & Forecast

6.3.5.2.1. By Product Type

6.3.5.2.2. By Technique

6.3.5.2.3. By End user

7. North America Renal Biomarkers Market Outlook

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Product Type

7.2.2. By Technique

7.2.3. By End user

7.2.4. By Country

7.3. North America: Country Analysis

7.3.1. United States Renal Biomarkers Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Product Type

7.3.1.2.2. By Technique

7.3.1.2.3. By End user

7.3.2. Mexico Renal Biomarkers Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Product Type

7.3.2.2.2. By Technique

7.3.2.2.3. By End user

7.3.3. Canada Renal Biomarkers Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Product Type

7.3.3.2.2. By Technique

7.3.3.2.3. By End user

8. South America Renal Biomarkers Market Outlook

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Product Type

8.2.2. By Technique

8.2.3. By End user

8.2.4. By Country

8.3. South America: Country Analysis

8.3.1. Brazil Renal Biomarkers Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Product Type

8.3.1.2.2. By Technique

8.3.1.2.3. By End user

8.3.2. Argentina Renal Biomarkers Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Product Type

8.3.2.2.2. By Technique

8.3.2.2.3. By End user

8.3.3. Colombia Renal Biomarkers Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Product Type

8.3.3.2.2. By Technique

8.3.3.2.3. By End user

9. Middle East and Africa Renal Biomarkers Market Outlook

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Product Type

9.2.2. By Technique

9.2.3. By End user

9.2.4. By Country

9.3. MEA: Country Analysis

9.3.1. South Africa Renal Biomarkers Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Product Type

9.3.1.2.2. By Technique

9.3.1.2.3. By End user

9.3.2. Saudi Arabia Renal Biomarkers Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Product Type

9.3.2.2.2. By Technique

9.3.2.2.3. By End user

9.3.3. UAE Renal Biomarkers Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value

9.3.3.2. Market Share & Forecast

9.3.3.2.1. By Product Type

9.3.3.2.2. By Technique

9.3.3.2.3. By End user

9.3.4. Egypt Renal Biomarkers Market Outlook

9.3.4.1. Market Size & Forecast

9.3.4.1.1. By Value

9.3.4.2. Market Share & Forecast

9.3.4.2.1. By Product Type

9.3.4.2.2. By Technique

9.3.4.2.3. By End user

10. Market Dynamics

10.1. Drivers

10.2. Challenges

11. Market Trends & Developments

11.1. Recent Developments

11.2. Product Launches

11.3. Mergers & Acquisitions

12. Global Renal Biomarkers Market: SWOT Analysis

13. Porter’s Five Forces Analysis

13.1. Competition in the Industry

13.2. Potential of New Entrants

13.3. Power of Suppliers

13.4. Power of Customers

13.5. Threat of Substitute Product

14. Competitive Landscape

14.1. Abbott Laboratories

14.1.1. Business Overview

14.1.2. Company Snapshot

14.1.3. Product & Services

14.1.4. Current Capacity Analysis

14.1.5. Financials (In case of listed)

14.1.6. Recent Developments

14.1.7. SWOT Analysis

14.2. Beckman Coulter Inc. (Danaher Corporation)

14.3. bioMerieux SA

14.4. BioPorto A/S

14.5. Bio-Rad Laboratories Inc.

14.6. Enzo Biochem Inc.

14.7. F. Hoffmann-La Roche AG

14.8. PerkinElmer Inc.

14.9. Randox Laboratories Ltd.

14.10. Siemens AG

14.11. Thermo Fisher Scientific Inc.

15. Strategic Recommendations

16. About Us & Disclaimer

Figures and Tables

Frequently asked questions

What was the market size of the Global Renal Biomarkers Market in 2022?

The market size of the Global Renal Biomarkers Market was estimated to be USD 1.31 billion in 2022.

What is the Study Period for the Global Renal Biomarkers Market?

The Global Renal Biomarkers Market was analyzed for the historical period of 2018 to 2021. While the base year was 2022, estimation for the year 2023 was calculated and the market growth was further forecast for 2024 to 2028.

Who are the top players operating in the Global Renal Biomarkers Market in 2022?

Abbott Laboratories, Beckman Coulter Inc. (Danaher Corporation), bioMerieux SA, BioPorto A/S, Bio-Rad Laboratories Inc., Enzo Biochem Inc., F. Hoffmann-La Roche AG, PerkinElmer Inc., Randox Laboratories Ltd., Siemens AG, Thermo Fisher Scientific Inc. are the top players operating in the Global Renal Biomarkers Market in 2022.

What are the major drivers for the Global Renal Biomarkers Market?

Rising prevalence of kidney diseases and increased drug development and clinical trials are the major drivers for the Global Renal Biomarkers Market.

Related Reports

Sakshi Bajaal

Business Consultant

Talk To Analyst

Press Release

Renal Biomarkers Market to Grow with a CAGR of 7.25% through 2028

Nov, 2023

Rising prevalence of kidney diseases and increased drug development and clinical trials are factors driving the Global Renal Biomarkers Market in the forecast period 2024-2028.